Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Recipharm Provides Access to Asmasal Clickhaler Dossier for Vectura plc Chinese Market Approval

Published: Tuesday, July 16, 2013
Last Updated: Tuesday, July 16, 2013
Bookmark and Share
Recipharm currently supply the product to markets in the UK and France.

Recipharm AB has announced that it is working with Vectura Group plc to provide access to its license for the regulatory dossier of Asmasal® for the Chinese regulatory authorities as part of the Chinese market approval process.

The regulatory submission will be led by Vectura’s recently announced new strategic joint venture, Tianjin Kinnovata Pharmaceutical Company Limited (Kinnovata), (http://www.vectura.com/media/press-releases/2013/13-may-2013.aspx).

Asmasal® Clickhaler® is a dry powder inhaler which contains the active ingredient salbutamol which is used in conditions where there is narrowing of the airways, such as asthma or chronic obstructive pulmonary disease (COPD).

Vectura’s Clickhaler® device allows the active to be delivered directly into the lungs.

An application for the import of Asmasal® Clickhaler® (salbutamol) has been filed with the Chinese State Food and Drug Administration (SFDA) and this collaboration will see Recipharm manufacturing finished product for Kinnovata and the Chinese market.

Recipharm will also provide technical assistance to Kinnovata to transfer the manufacturing know-how to Kinnovata facilities in China.

“We are happy to be involved with Vectura’s joint venture in the Chinese pharma market and we believe that we can contribute to this, not just from providing access to the product but also from providing services to Kinnovata until its local manufacturing is up and running” says Carl-Johan Spak, Executive Vice President, Development & Technology at Recipharm.

China’s pharmaceutical market, is growing at a rapid rate and is expected to reach $40B in market size in 2020, making it the 3rd largest pharmaceutical market worldwide.

Recent estimates suggest the overall incidence of asthma in China is approximately 2.0%; of a patient population of more than 25 million people.

COPD is an even bigger challenge, with approximately 42 million people suffering in China, and forecasts estimate that this number will increase to nearly 56 million by 2021.

The agreement between Recipharm and Vectura provides an opportunity for a well established product to be used to help fill the need for affordable treatment in China.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Recipharm Acquisitions Create Global CDMO Leader
Recipharm has announced that it has signed two separate agreements to acquire Kemwell’s pharmaceutical contract development and manufacturing (CDMO) businesses.
Tuesday, April 19, 2016
Recipharm Takes the Lead in Serialisation Challenge with €40m Investment
The company has unveiled that it plans to invest €40m over the next three years to ensure solutions for serialisation processes.
Thursday, February 11, 2016
Recipharm Presents 2016 International Environmental Award Winner
Jerker Frick won the award in recognition of his research into the environmental effects of pharmaceuticals.
Tuesday, February 02, 2016
Recipharm Appoints New Key Account Director for Europe
Company announces appointment of Anke Mollowitz.
Thursday, January 21, 2016
Recipharm Appoints General Manager
Company appoints Yves Buelens for its new blow fill seal subsidiary in Kaysersberg, France.
Saturday, January 09, 2016
Recipharm Signs Manufacturing Agreement with Alcon
Company acquires facility in France, adding new niche capabilities.
Tuesday, December 22, 2015
Recipharm and LIDDS Sign Contract
Contract for production of Liproca® Depot and investment in LIDDS.
Thursday, December 17, 2015
Recipharm Secures €25 Million Contract with Daewoong Pharmaceutical
Company has signed an agreement with Daewoong for the manufacture and supply of Erdosteine API.
Tuesday, November 24, 2015
Recipharm Announces Signing of an Agreement with Daewoong
Company secures €25 million contract for Erdosteine API with Daewoong Pharmaceutical.
Saturday, November 14, 2015
Recipharm to Acquire Majority Stake in Indian CMO Nitin Lifesciences
Company enters into an agreement to acquire Indian sterile injectables CMO, Nitin Lifesciences.
Wednesday, October 28, 2015
Recipharm Appoints New Business Director for Italy
Company also appoints new General Manager at Pessac, France.
Tuesday, October 27, 2015
Recipharm Reaches Agreement with LobSor Pharmaceuticals
Agreement to manufacture LECIGON™, a proprietary treatment for advanced Parkinson’s disease.
Thursday, September 10, 2015
Recipharm Signs Agreement with RedHill Biopharma
Agreement for manufacturing of RHB-105 for treatment of H. pylori infection.
Thursday, August 27, 2015
Recipharm Secures Additional Bank Financing for Continued Growth
Company has entered a new five-year SEK 1 500 million term loan facility with three of the largest banks.
Tuesday, July 14, 2015
Recipharm Invests SEK 8 Million in Pharmanest
Investment to support the development of Pharmanest’s lead drug candidate SHACT.
Friday, July 10, 2015
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Apricot Kernels Pose Risk of Cyanide Poisoning
Eating more than three small raw apricot kernels, or less than half of one large kernel, in a serving can exceed safe levels. Toddlers consuming even one small apricot kernel risk being over the safe level.
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
A lncRNA Regulates Repair of DNA Breaks in Breast Cancer Cells
Findings give "new insight" into biology of tough-to-treat breast cancer.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!